^
Association details:
| Biomarker: | SDHB deletion |
|---|---|
| Cancer: | Gastrointestinal Stromal Tumor |
| Drug: | Focus V (anlotinib) (Multi-tyrosine kinase inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Activity of Anlotinib in the Second-Line Therapy of Metastatic Gastrointestinal Stromal Tumors: A Prospective, Multicenter, In Vitro Study
Published date:
02/13/2023
Excerpt:
In addition, 1 patient with PDGFRA D842V mutation got 8.5 months PFS and no tumor progression happened and 3 patients with SDHB-deficient GIST had average of 16 months PFS....In summary, anlotinib showed moderate antitumor activity in drug-resistant GIST cell lines in vitro, and acceptable PFS and good tolerance were obtained in this prospective study.
DOI:
10.1093/oncolo/oyac271
